Law360, New York (February 01, 2012, 6:52 PM ET) -- A Massachusetts federal judge on Wednesday refused to dismiss multidistrict antitrust litigation accusing Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market and forcing direct purchasers to pay higher prices for the drug.
U.S. District Judge Rya W. Zobel rejected Astellas' contention that its September 2007 citizen petition to the U.S. Food and Drug Administration arguing for further testing of Prograf's generic equivalent, tacrolimus, was shielded from antitrust action as protected speech by the First Amendment.
The direct purchaser...
Astellas Can’t Shake MDL Over Generic Prograf Delays
To view the full article, take a free trial now.
